TRDA Q2 2024 Earnings — Entrada Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TRDAEntrada Therapeutics, Inc.

$502M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$95M+421.2% YoY

Gross Profit

$95M100.0% margin

Operating Income

$53M56.4% margin

Net Income

$55M58.1% margin

EPS (Diluted)

$1.55

QoQ Revenue Growth

+60.2%

Cash Flow

Operating Cash Flow

$40M

Free Cash Flow

$39M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$582M

Total Liabilities

$152M

Stockholders' Equity

$430M

Cash & Equivalents

$185M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$95M	$18M	+421.2%
Gross Profit	$95M	-$8M	+1264.7%
Operating Income	$53M	-$16M	+427.8%
Net Income	$55M	-$26M	+312.2%

Revenue Segments

License

$71M100%